- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Specialty Pharmacy Management Trends
Debbie Stern, RPh; Becki Fenrick, PharmD, MBA; and Michael Fine, MD, presented on specialty pharmacy management trends on Friday.
Debbie Stern, RPh; Becki Fenrick, PharmD, MBA; and Michael Fine, MD, presented on specialty pharmacy management trends on Friday at the Academy of Managed Care Pharmacy (AMCP) 24th Annual Meeting.
The presenters touched on a number of updates to the EMD Serono Specialty Digest. For starters, more detailed analysis of prior authorization and preferred product strategies is provided by therapy category. In addition, strategies related to palliative and end-of-life care for oncology patients are clearly identified. Payers also provided input on specific interventions and outcome measures for hepatitis C, multiple sclerosis, oncology, and rheumatoid arthritis.
Following the overview and introduction, the presenters then shared data from the surveys that had been given for the 8th edition of the EMD Serono Specialty Digest. Here are some of the general findings:
When asked to rank of a scale of 1-5 the factors determining classification as specialty pharmacy, here is how those polled responded:
- High cost (84%)
- Requires special handling (68%)
- Treats rare disease (63%)
- Limited distribution (63%)
- Requires ongoing assessment of response (47%)
- Requires patient administration training (38%)
- Requires monitoring of side effects (32%)
- Drug has an FDA mandated REMS (29%)
The presenters also touched on the top therapy categories specified by specialty pharmacy. The top 3 categories in 2011 were growth hormone disorder, rheumatoid arthritis/Crohn’s disease, and multiple sclerosis.
Those polled were also asked to rank strategies to manage across pharmacy and medical benefits. The results were as follows:
- Clinical criteria covers the entire therapy category across benefits (71%)
- Pharmacy department manages specialty drug PA across benefits (62%)
- Contract with one SPP to manage distribution of specialty drugs across benefits (38%)
- Allow “buy and bill” with same reimbursement rate for SPPs and physicians (31%)
- SPP manages specialty drugs across benefits (29%)
- Eliminate “buy and bill” for physicans with mandatory SPP across benefits (20%)
- Out-of-pocket maximum across the benefits (13%)
- Equal cost share for specialty drugs across benefits (6%)
- Non-SPP external vendor manages specialty drug PA across benefits (6%)
The speakers also discusses some of the current specialty drug trends and issues, such as an increasing number and cost of specialty drugs, reimbursement isses as they relate to the regulatory picture and healthcare reform, and increased utilization management.
For more information about this presentation, please visit www.amcp.org.
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
